Highlights a novel mechanism where plasma kallikrein deficiency reduces thrombosis through Mas receptor upregulation and tissue factor suppression.
In this issue of Blood , Stavrou et al show that in plasma kallikrein–deficient mice ( Klkb1 −/− ), upregulation of the Mas receptor in the renin-angiotensin system leads to prostacyclin-mediated suppression of vessel wall tissue factor (TF), which leads to reduced thrombosis independent of
No takes yet. Share an insight, caveat, or question.
Thomas Renné (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: